NO-platform
NO platform allows you to synthesize original hybrid molecules consisting of pharmaceutically active compounds (API), prostaglandins (PG) and nitric oxide donors (NO-donors)
Main News
* Gurus successfully completed preclinical trials of asthma treatment drug * Magazine Kommersant published an article about promising multifunctional drug candidates of Gurus BioPharm * Gurus raises $0.7M for preclinical trials of a drug for asthma

28.08.2015  Gurus launches preclinical trials of innovative drug candidate GUR-501 for asthma treatment